Screener
Amphastar Pharmaceuticals AMPH Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
FAQ
- What is Amphastar Pharmaceuticals's total liabilities?
- Amphastar Pharmaceuticals (AMPH) reported total liabilities of $975.61M in Q2 2026.
- How has Amphastar Pharmaceuticals's total liabilities changed year-over-year?
- Amphastar Pharmaceuticals's total liabilities increased by 13.7% year-over-year, from $857.85M to $975.61M.
- What is the long-term trend for Amphastar Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's total liabilities has grown at a 35.7% compound annual growth rate (CAGR), from $182.51M to $840.49M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Amphastar Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude